Lexicon says Phase 2b data support pilavapadin 10 mg for Phase 3 DPNP trial

Lexicon Pharmaceuticals, Inc. -1.79%

Lexicon Pharmaceuticals, Inc.

LXRX

1.65

-1.79%

  • Lexicon Pharmaceuticals scheduled new Phase 2b PROGRESS data on pilavapadin in diabetic peripheral neuropathic pain for presentation April 22 at American Academy of Neurology annual meeting in Chicago.
  • Updated findings supported selection of 10 mg as dose for Phase 3 development, based on improved patient-reported pain outcomes versus placebo.
  • Tolerability profile for 10 mg over eight weeks remained broadly comparable to placebo, with few treatment-related discontinuations.
  • Additional preclinical results on pilavapadin in spasticity models of multiple sclerosis or spinal cord injury are set for poster presentation April 20, expanding focus on AAK1 pathway in neurologic disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604170800PRIMZONEFULLFEED9691648) on April 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.